NextGen Healthcare, Clinical Decision Support Consortium and WVP Health Authority Join to Launch Clinical Decision Support Pilot

HORSHAM, Pa.-- NextGen Healthcare Information Systems, LLC., a wholly owned subsidiary of Quality Systems, Inc. (NASDAQ: QSII) and a leading provider of healthcare information systems and connectivity solutions, and Clinical Decision Support Consortium (CDSC) announced today the successful deployment of a clinical decision support tool aimed at making evidence-based clinical knowledge more readily available to healthcare providers. NextGen Healthcare client Willamette Valley Providers (WVP) Health Authority is one of the first clinical sites with a commercial electronic health record (EHR) to take the program live.

In 2008, Brigham and Women’s Hospital (BWH), part of Partners HealthCare System, founded the CDSC, which competed for and received a research contract from the Agency for Healthcare Research and Quality (AHRQ). CDSC members– leading healthcare provider organizations and EHR vendors, including NextGen Healthcare – worked together to develop, implement and evaluate approaches for incorporating clinical decision support (CDS) into the delivery of healthcare. The CDS Consortium aims to advance that mission by establishing nationwide consistencies for clinical decision support recommendations. This aids in ensuring providers are not entirely reliant upon disparate vendors and product upgrades to receive the most up-to-date evidence-based recommendations.

To achieve this level of consistency, Partners HealthCare created a technical environment that demonstrates successful clinical decision support across different platforms and electronic health records (EHR) systems. Currently, the process involves:

  • a provider sending a request for clinical decision support via NextGen® Ambulatory EHR;
  • the NextGen® system creating an industry-standard Continuity of Care Document (CCD) with a patient’s deidentified clinical data;
  • the CCD is delivered to the Partners’ Enterprise Clinical Rules Service (ECRS), where it is analyzed;
  • Partners returns an Extensible Markup Language (XML) message with recommendation(s) appropriate for the given patient; and,
  • recommendation(s) are immediately displayed to the provider in NextGen Ambulatory EHR without breaking existing workflow.

The solution will continue to be tested by Salem, Oregon-based WVP Health Authority, an association of approximately 530 members practicing primary and specialty care. Data from an ongoing pilot will be collected for six months and analyzed to evaluate the effectiveness of patient information transfer to Partners and care recommendations back to WVP’s physicians.

“The Clinical Decision Support Consortium achieved a critical objective: delivery of evidence-based, consensus driven clinical decision support to multiple disparate EMRs at scale”, explained Dr. Blackford Middleton, the founding principal investigator of the CDSC. “This achievement represents not only the ability to harmonize knowledge representation and key parameters of clinical decision support rules, but also the ability to deliver those rules as web services to a variety of EMRs, and in different places in the EMR workflow. These demonstration projects and their success point the way forward toward creation of an ecosystem of clinical decision support providers offering the end-user an array of choices for clinical decision support, and alleviating the need for local knowledge engineering and management to achieve decision-support at scale. This is a critical step toward achieving the value potential of EMR implementation in this country, and around the world.”

“Historically, research and development of CDS systems has largely taken place at academic medical centers rather than at community-based practices. As a HCIT leader, participating in a project such as this, allows us to help shape best practices for integrating CDS directly into ambulatory EHRs,” said Dr. Greg Fraser, chief medical information officer for WVP Health Authority. “With the right partners and the right collaboration, we executed this proof of concept and look forward to connecting the system’s wealth of clinical content to evidence-based guidelines, helping ensure our providers have the most comprehensive information possible at the point of care.”

“The success of this project suggests that using this type of centralized CDS, populated with consensus approved recommendations for evidence-based care, can be deployed across diverse settings, resulting in improved outcomes and lower costs,” said Dr. Sarah T. Corley, chief medical officer for NextGen Healthcare. “This partnership is a truly integrated, collaborative and strategic approach to clinical data-sharing, and our expertise has positioned NextGen as an effective partner in this cutting-edge research.”

About AHRQ

The Agency for Healthcare Research and Quality's (AHRQ) mission is to improve the quality, safety, efficiency, and effectiveness of health care for all Americans. As one of 12 agencies within the Department of Health and Human Services, AHRQ supports research that helps people make more informed decisions and improves the quality of health care services.

About Partners Healthcare

Partners HealthCare is an integrated health system founded by Brigham and Women’s Hospital and Massachusetts General Hospital. In addition to its two academic medical centers, the Partners system includes community and specialty hospitals, a managed care organization, community health centers, a physician network, home health and long-term care services, and other health-related entities. Partners Healthcare is one of the nation’s leading biomedical research organizations and a principal teaching affiliate of Harvard Medical School. Partners HealthCare is a non-profit organization. For more information, please visit http://www.partners.org/.

About WVP Health Authority

WVP Health Authority is an Independent Provider Association (IPA) that offers Medicare and Medicaid services to individuals in the Mid-Willamette Valley. For the past 20 years, WVP Health Authority has utilized its dedicated clinical and administrative staff to provide quality healthcare in a cost efficient manner. Today, the roughly 500 physicians who are represented by WVP Health Authority collaborate to provide care to over 60,000 Medicare and Medicaid members in the region. As the organization moves forward, it anticipates continued improvement through the strong community partnerships, passionate medical professionals, and an innovative approach that has defined WVP as an organization. For more information, please visit www.wvphealthauthority.org.

About NextGen Healthcare

NextGen Healthcare Information Systems, LLC, a wholly owned subsidiary of Quality Systems, Inc., provides integrated clinical, connectivity and financial solutions, including revenue cycle management services for ambulatory, inpatient and dental provider organizations. For more information, please visit www.nextgen.com and www.qsii.com. Follow NextGen Healthcare on Twitter at www.twitter.com/nextgen, Facebook at http://www.facebook.com/NextGenHealthcare or LinkedIn at http://www.linkedin.com/company/nextgen-healthcare-information-systems.

This news release may contain forward-looking statements within the meaning of the federal securities laws. Statements regarding future events, developments, the Company's future performance, as well as management's expectations, beliefs, intentions, plans, estimates or projections relating to the future (including, without limitation, statements concerning revenue and net income), are forward-looking statements within the meaning of these laws and involve a number of risks and uncertainties. Management believes that these forward-looking statements are reasonable and are based on reasonable assumptions and forecasts, however, undue reliance should not be placed on such statements that speak only as of the date hereof. Moreover, these forward-looking statements are subject to a number of risks and uncertainties, some of which are outlined below. As a result, actual results may vary materially from those anticipated by the forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: volume and timing of systems sales and installations; length of sales cycles and installation process; the possibility that the products will not achieve market acceptance; seasonal patterns of sales and customer buying behavior; the development by competitors of new or superior technologies; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; undetected errors or bugs in software; product liability; changing economic, political or regulatory influences in the health-care industry; changes in product-pricing policies; availability of third-party products and components; competitive pressures including product offerings, pricing and promotional activities; the Company's ability or inability to attract and retain qualified personnel; possible regulation of the Company's software by the U.S. Food and Drug Administration; uncertainties concerning threatened, pending and new litigation against the Company including related professional services fees; uncertainties concerning the amount and timing of professional fees incurred by the Company generally; changes of accounting estimates and assumptions used to prepare the prior periods' financial statements; general economic conditions; and the risk factors detailed from time to time in Quality Systems' periodic reports and registration statements filed with the Securities and Exchange Commission. A significant portion of the Company's quarterly sales of software product licenses and computer hardware is concluded in the last month of the fiscal quarter, generally with a concentration of such revenues earned in the final ten business days of that month. Due to these and other factors, the Company's revenues and operating results are very difficult to forecast. A major portion of the Company's costs and expenses, such as personnel and facilities, are of a fixed nature and, accordingly, a shortfall or decline in quarterly and/or annual revenues typically results in lower profitability or losses. As a result, comparison of the Company's period-to-period financial performance is not necessarily meaningful and should not be relied upon as an indicator of future performance. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.